Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2011-08-02
2011-08-02
Hui, San-ming (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C514S646000
Reexamination Certificate
active
07989499
ABSTRACT:
The present invention is directed to methods of modulating the activity of an isoform of manganese superoxide dismutase which is useful for the treatment of diseases such as neurodegenerative diseases and heart failure.
REFERENCES:
patent: 4933324 (1990-06-01), Shashoua
patent: 4939174 (1990-07-01), Shashoua
patent: 5013759 (1991-05-01), Berman
patent: 5112863 (1992-05-01), Hashimoto et al.
patent: 5202357 (1993-04-01), Bowser et al.
patent: 5284876 (1994-02-01), Shashoua et al.
patent: 5540911 (1996-07-01), Hartman et al.
patent: 5618955 (1997-04-01), Mechoulam et al.
patent: 6107499 (2000-08-01), Shashoua
patent: 6258836 (2001-07-01), Shashoua
patent: 6407137 (2002-06-01), Shashoua
patent: 6602902 (2003-08-01), Shashoua et al.
patent: 6713511 (2004-03-01), Yehuda
patent: 6737506 (2004-05-01), Anziano
patent: 7144994 (2006-12-01), Anziano
patent: 7227001 (2007-06-01), Anziano
patent: 2004/0122089 (2004-06-01), Martin et al.
patent: 2004/0209959 (2004-10-01), Hogestatt et al.
patent: 2004/0242655 (2004-12-01), Anziano
patent: 2006/0025385 (2006-02-01), Atlas
patent: 2010/0028348 (2010-02-01), Anziano
patent: WO 99/43697 (1999-09-01), None
patent: WO 2004/069146 (2004-08-01), None
patent: WO 2005/001041 (2005-01-01), None
patent: WO 2006/086422 (2006-08-01), None
Janusz JM, Buckwalter BL, Young PA, LaHann TR, Farmer RW, Kasting GB, Loomans ME, Kerckaert GA, Maddin CS, Berman EF, et al., “Vanilloids. 1. Analogs of capsaicin with antinociceptive and antiinflammatory activity,” Journal of Medicinal Chemistry, Sep. 1993, 36(18), 2595-2604.
U.S. Appl. No. 10/858,450, filed May 2004, Anziano.
Bisogno T, Melck D, Bobrov MYu, Gretskaya NM, Bezuglov VV, De Petrocellis L, and Di Marzo V, “N-acyl-dopamines: novel synthetic CB(1) cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo,” The Biochemical Journal, Nov. 2000, 351 Pt 3, 817-824.
Szeto, H.H., Mitochondria-Targeted Peptide Antioxidants: Novel Neuroprotective Agents, AAPSJ, (2006), 8 (3) 521-31, Arlington, VA.
Eaton, et al., “Formation of 4-hydroxy-2-nonenal-modified proteins in ischemic rat heart”, Am. J. Physiol. (1999) 276: H935-H943.
Anguera, Montserrat C., et al., Methenyltetrahydrofolate Synthetase is a High-Affinity Catecholamine-Binding Protein, Arch Biochem Biophys, Nov. 15, 2006; 455(2) 175-187.
DiMarzo, Vincenzo, et al., Interactions between synthetic vanilloids and the endogenous cannabinoid system, FEBS Letters, vol. 436, Issue 3, pp. 449-454 (1998).
NCBI Pub Chem Database; CID11560744 dated Oct. 26, 2006.
Winstanley, Keith J., et al., Ortho-Substituted Catechol Derivatives: The Effect of Intramolecular Hydrogen-Bonding Pathways on Chloride Anion Recognition, J. Org. Chem. 2007, 72, 2803-2815.
NCBI Pub Chem Database; CID13309825 dated Feb. 8, 2007.
NCBI Pub Chem Database; CID11996946 dated Feb. 5, 2007.
NCBI Pub Chem Database; CID20250866 dated Dec. 5, 2007.
Alexander, et al., “Mechanism of Carbamate Inactivation of FAAH: Implications for the Design of Covalent Inhibitors and In Vivo Functional Probes for Enzymes,” J . Chembiol. (2005) 12:1179-1187.
Anziano, et al., “Expression of an isoform of magnesium superoxide dismutase in a child with multiple deletions of the human mitochondrial DNA,” Pediatrics Res. (2000) 47:238A.
Aries, et al., “Essential role of GATA-4 in cell survival and drug-induced cardiotoxicity,” Proc. Natl. Acad. Sci. USA (2004) 101:6975-6980.
Arola, et al., “Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis,” Cancer Res. (2000) 60:1789-1792.
Bacot, et al., “Covalent binding of hydroxy-alkenals 4-HDDE, 4-HHE, and 4-HNE to ethanolamine phospholipid subclasses,” J. Lipid Res. (2003) 44:917-926.
Bezuglov V, et al., “Synthesis and biological evaluation of novel amides of polyunsaturated fatty acids with dopamine,” Bioorganic &Medicinal Chemistry Letters, Pergamon, Elsevier Science, GB, vol. 11, No. 4, Feb. 26, 2001 pp. 447-449.
Bisogno, T., et al., “Arachidonoylserotonin and other novel inhibitors of fatty acid amide hydrolase,” Biochemical and Biophysical Research Communications, vol. 248, No. 3, Jul. 30, 1998, pp. 515-522.
Roche, Edward B. , “Bioreversible Carriers in Drug Design,” American Pharmaceutical Association and Pergamon Press, 1987 (voluminous).
Boger, et al., “Exceptionally potent inhibitors of fatty acid amide hydrolase: the enzyme responsible for degradation of endogenous oleamide and anandamide,” Proc. Natl. Acad. Sci. USA (2000) 97:5044-5049.
Borg, et al., “Recognition of extracellular matrix components by neonatal and adult cardiac myocytes,” Dev. Biol. (1984) 104:86-96.
Brame, et al., “Identification of extremely reactive gamma-ketoaldehydes (isolevuglandins) a products of the isoprostane, pathway and characterization of their lysyl protein adducts,” J. Biol. Chem. (1999) 274:13139-13146.
Bugaisky, et al., “Differentiation of adult rat cardiac myocytes in cell culture,” Circulation Res. (1989) 64:493-500.
Cracowski, et al., “Vascular biology of the isoprostanes,” J. Vasc. Res. (2001) 38:93-103.
De Petrocellis, L., et al., “Endocannabinoids and fatty acid amides in cancer, inflammation and related disorders,” Chemistry and Physics of Lipids 2000 IE, vol. 108, No. 1-2, 2000, pp. 191-209.
Deutsch, D.G., Glaser, S.T., Howell, J.M., et al. The cellular uptake of anandamide is coupled to its breakdown by fatty-acid amide hydrolase. J Biol Chem 276(10) 6967-6973 (2001).
Di Marzo, V., et al., “Cannabimimetic fatty acid derivatives in cancer and inflammation,” Prostaglandins &Other Lipid Mediators Apr. 2000, vol. 61, No. 1-2, pp. 43-61.
European Supplemental Search Report dated Jul. 15, 2009 for European Patent Application No. 04753806.1.
Fajardo, et al., “Endocannabinoid Inhibition: A New Cardioprotective Strategy Against Doxorubicin Cardiotoxicity,” J. American College of Cardiology (2007) 50(6):537-539.
Fegley, D., Kathuria, S., Mercier, R., et al. Anandamide transport is independent of fatty-acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1172. Proc Natl Acad Sci USA 101(23) 8756-8761 (2004).
Gewies, A., et al., “Cytochrome c Is Involved in Fas-mediated Apoptosis of Prostatic Carcinoma Cell Lines,” Cancer Research, 60:2163-2168; 2000.
Green, T.W., et al., “Protective Groups in Organic Synthesis,” 3rd Edition, John Wiley & Sons, Inc., 1999 (voluminous).
Grune and Davies, “The proteasomal system and HNE-modified proteins,” Mol. Aspects Med. (2003) 24:195-204.
Higuchi, T., et al., “Pro-drugs as Novel Delivery Systems,” vol. 14 of the A.C.S. Symposium Series, 1974, Forward and Preface only, (voluminous).
Hoff, H. F., et al., “Oxidation of LDL: Role in Atherogenesis,” Klin Wochenschr (1991) 69:1032-1038.
Janssen, “The pulmonary biology of isoprostanes,” Chem. Phys. Lipids (2004) 128:101-116.
Khanolkar, A.D., Makriyannis, A. Structure-activity relationships of anandamide, an endogenous cannabinoid ligand. Life Sci 65 607-616 (1999).
Keefe, “Trastuzumab-associated cardiotoxicity,” Cancer (2002) 95:1592-1600.
Kemp, et al, “Organic Chemistry,” Worth Publishers, Inc. NY (voluminous), 1980.
Kitta, et al., “Hepatocyte growth factor induces GATA-4 phosphorylation and cell survival in cardiac muscle cells,” J. Biol. Chem. (2003) 278:4705-4712.
Li, Yibling, et al., “Dilated Cardiomyopathy and Neonatal Lethality in Mutant Mice Lacking Manganese Superoxide dismutase,” Nature Genetics, vol. 11, Dec. 1995.
March, J., “Advanced Organic Chemistry,” 4th Edition, John Wiley & Sons, Inc., 1992 (voluminous).
Melck, D., et al., “Unsaturated long-chain N-acyl-vanillyl-amides (N-AVAMs): vanilloid receptor ligands that inhibit anandamide-facilitated transport and
Fox Rothschild LLP
Hui San-ming
MitoTek, LLC
Zarek Paul
LandOfFree
Compositions and methods for inhibiting an isoform of human... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for inhibiting an isoform of human..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for inhibiting an isoform of human... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2794541